Dennis Gillings - Iqvia Holdings Executive Chairman of the Board

Dr. Dennis B. Gillings, CBE, Ph.D. is Lead Director of the Company. He also served as Quintiles Executive Chairman from December 2012 to December 2015 and as Chief Executive Officer of Quintiles from 1982 to December 2012. Since 2016 Dr. Gillings has served as Chief Executive Officer of PharmaBio Development, a biotechnology investment fund. Dr. Gillings taught for more than 15 years as a professor at the University of North Carolina at Chapel Hill. Dr. Gillings has served on several other boards and councils, including the International Advisory Council to Singapore, the International Advisory Board for the Scottish Enterprise, and the Advisory Board of the Schaeffer Health Policy Institute at the University of Southern California. He served as the founding Chairman of the Association of Clinical Research Organizations. He also served as a director of Icagen, Inc. from 1997 until June 2011. He was awarded the Commander in The Most Excellent Order of the British Empire in 2004. Dr. Gillings served as Pro Chancellor of the University of Southampton from 2006 to 2011. In 2012, he received the SCRIP Lifetime Achievement Award in recognition of contributions to the pharmaceutical industry. Dr. Gillings received a diploma in Mathematical Statistics from Cambridge University in 1967 and a Ph.D. in Mathematics from the University of Exeter, England, in 1972. During 1996 to 1997, Dr. Gillings received honorary Professorships of Medicine from Beijing University, Peking Union Medical College, Shanghai University and Xian University
Age: 71  Chairman Since 2016  Ph.D    
Gillings has also received Honorary Doctorate degrees from the University of Exeter, the University of North Carolina at Chapel Hill, and the University of Southampton, Kings College, London and University College, London. He also became an Honorary Fellow at Queen Mary, University of London and the Academy of Medical Science, London.

Management Efficiency

The company has return on total asset of 4.03 % which means that for every 100 dollars spent on asset it generated profit of $4.03. This is acceptable considering the industry classification. Similarly, it shows return on equity (ROE) of 1.89 % implying that it made 1.89 on every $100 invested by shareholders.
The company has accumulated 9.77 B in total debt with debt to equity ratio (D/E) of 130.0 implying that the company may be unable to produce cash to meet its debt commitments. Iqvia Holdings has Current Ratio of 1.2 implying that it may have difficulties to pay its interest payments when they become due.

Similar Executives

Found 10 records


Jeffrey BezosAmazon Com
Yun MaAlibaba Group Holding Limited
Joseph TsaiAlibaba Group Holding Limited
Eric SchmidtAlphabet
Mark ZuckerbergFacebook
Art LevinsonApple
John ThompsonMicrosoft Corporation
Arthur LevinsonApple

Entity Summary

Quintiles IMS Holdings, Inc. offer biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the AsiaPacific. Iqvia Holdings (Q) is traded on BATS Exchange in USA and employs 36,100 people.

Iqvia Holdings Leadership Team

Thomas Pike, CEO and Director
Ari Bousbib, Director
Michael Evanisko, Independent Director
Leonard Schaeffer, Independent Director
James Erlinger, Executive Vice President General Counsel, Secretary
John Danhakl, Director
Richard Staub, President - Research and Development Solutions
Michael McDonnell, CFO, Executive Vice President
Kevin Gordon, COO
John Leonard, Independent Director
James Fasano, Director
Jonathan Coslet, Director
John Connaughton, Director
Haiyuan Lo, Director
Ronald Rittenmeyer, Director
Dennis Gillings, Executive Chairman of the Board
Todd Sisitsky, Director
Jack Greenberg, Independent Director
Kevin Knightly, President - Information and Technology Solutions

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Center Now


Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased few shares of
a day ago
Traded for 185.37
Purchased few shares of
a day ago
Traded for 194.88
Purchased few shares of
a day ago
Traded for 1350.8199
Purchased over 100 shares of
a day ago
Traded for 30.5
Purchased a lot of shares of
a day ago
Traded for 154.6
See also Your Equity Center. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.